Abstract
CD19-specific chimeric antigen receptor (CAR)+ T cells have demonstrated clinical efficacy and long-lasting remissions, concomitant with tolerable normal B-cell aplasia. However, many tumor-associated antigens (TAAs) are expressed on normal tissues, the destruction of which would lead to intolerable toxicity. Thus, there is a need to engineer CAR+ T cells with improved safety profiles to restrict toxicity against TAA-expressing normal tissues. Bioengineering approaches include: (i) targeting CAR+ T cells to the tumor site, (ii) limiting CAR+ T-cell persistence, and (iii) restricting CAR activation. We review and evaluate strategies to engineer CAR+ T cells to reduce the potential of on-target, off-tissue toxicity.
Original language | English (US) |
---|---|
Article number | e1271857 |
Journal | OncoImmunology |
Volume | 8 |
Issue number | 10 |
DOIs | |
State | Published - 2019 |
Keywords
- Bioengineering
- T cell
- chimeric antigen receptor
- on-target toxicity
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology